Parasol Med Tech
Developing an investigational, patient-specific left atrial appendage closure system for stroke prevention.
Website: https://www.parasolmed.com/home/careers-2/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Parasol Med Tech |
| Tagline | Developing an investigational, patient-specific left atrial appendage closure system for stroke prevention. |
| Headquarters | Hinsdale, Illinois, US |
| Founded | 2026 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | Pre-seed |
| Total Disclosed | ~$3,000,000 |
Links
From the public record
- Website: https://www.parasolmed.com
- LinkedIn: https://www.linkedin.com/in/evan1singer/
The Short Version
PUBLIC Parasol Med Tech is a University of Chicago spinout developing an investigational, patient-specific left atrial appendage closure system for stroke prevention in atrial fibrillation, and it merits attention now because it has moved quickly from university-backed seed support to a $2.75 million pre-seed financing around a differentiated structural heart concept [Polsky Center, October 2026] [Polsky Center, June 2026]. The founding story is straightforward but credible: the company emerged from the clinical work of Atman Shah, an interventional cardiologist and University of Chicago professor whose practice includes catheter-based interventions and left atrial appendage closure, which gives the program a clinician-originated view of an established procedural pain point [Polsky Center, June 2026] [Polsky Center, October 2026].
The product thesis rests on an integrated catheter-and-gel closure system designed to conform to patient anatomy and reduce reliance on a permanent metal implant, a positioning that suggests differentiation at the device design level rather than through software alone [Polsky Center, October 2026] [PitchBook]. Public evidence still places the technology in prototype development and preclinical testing, so the investment case at this stage is less about commercial traction than about whether the team can convert anatomical fit and implant-free intent into defensible preclinical and, later, clinical data [Polsky Center, October 2026] [Polsky Center, June 2026].
Team quality is the clearest early strength in the public record. Shah brings direct procedural domain expertise, while University of Chicago materials reported in June that Evan Singer had recently joined as CEO, a role also reflected in later public profiles and deal databases, although fuller detail on Singer's operating track record is limited in the sources reviewed here [Polsky Center, June 2026] [LinkedIn, 2026] [Global Deal Flow, 2026].
On capitalization, Parasol has disclosed two pre-seed financings: a $250,000 George Shultz Innovation Fund investment in June 2026 and a $2.75 million oversubscribed pre-seed round announced in October 2026 with participation from Harper Court Ventures, UCM Ventures, and Cardiovascular Innovation Ventures [Polsky Center, June 2026] [Polsky Center, October 2026]. The business model is best understood as hardware plus software within medtech, but near-term value creation will depend more on R&D execution, preclinical progress, and eventual regulatory path clarity than on any visible go-to-market motion [Crunchbase] [Polsky Center, October 2026].
Over the next 12 to 18 months, the public milestones that matter are concrete: prototype maturation, preclinical readouts, clearer regulatory sequencing, and any evidence that the company can assemble the clinical and manufacturing partnerships needed to move beyond a university-originated concept [Polsky Center, June 2026] [Polsky Center, October 2026]. That is a narrow but understandable set of proofs for a structural heart startup at this age, and the present record supports cautious interest rather than broad extrapolation.
Unconfirmed -- This section relies materially on company-adjacent and university-affiliated sources, with partial corroboration from PitchBook, LinkedIn, Global Deal Flow, and Crunchbase.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Pre-seed, total disclosed about $3.0 million |
The Company in Brief
From the public record
Parasol Med Tech appears to be a newly formed University of Chicago spinout focused on left atrial appendage closure, with public databases describing the company as based in Hinsdale, Illinois and founded in 2026 [Crunchbase]. The plain reading of the early record is that the company is still at formation-stage rather than commercial scale: Crunchbase classifies it as a pre-seed medtech business, while PitchBook describes the product concept as patient-specific left atrial appendage closure implants delivered by transcatheter approach [Crunchbase] [PitchBook, 2026].
The public milestone trail is short but directionally useful. In June 2026, Parasol was named as a recipient of a $250,000 George Shultz Innovation Fund investment, tied to prototype development and preclinical work around the companys investigational LAA closure platform [Polsky Center, June 2026]. By October 2026, the company had announced a $2.75 million pre-seed round, which indicates a rapid move from university-backed formation support into institutionally backed seed financing within the same year [Polsky Center, October 2026].
The legal entity name is reflected in third-party deal tracking as Parasol Med Tech, Inc., though the structured public record provided here does not include a state filing extract to independently confirm incorporation details [Global Deal Flow, 2026]. On balance, the company overview is straightforward: a 2026 cardiac-device spinout headquartered in the Chicago area, formed around a clinician-led thesis in stroke prevention and still early in technical and regulatory development [Crunchbase] [PitchBook, 2026].
Single-source, plausible -- Headquarters and founding year are supported by Crunchbase, while chronology is supplemented by PitchBook and university-linked funding announcements rather than state filings or a company website profile.
What They Have Built
MIXED
The product claim worth focusing on is narrow and still early: Parasol Med Tech says it is developing an investigational, patient-specific left atrial appendage closure system for stroke prevention in people with atrial fibrillation [Polsky Center, October 2026]. Public descriptions are consistent on the basic architecture. Polsky Center describes an integrated catheter-and-gel LAA closure system designed to conform to individual patient anatomy and reduce the need for a permanent metal implant, while PitchBook characterizes the company as developing patient-specific LAA closure implants with transcatheter delivery capability [Polsky Center, October 2026] [PitchBook, 2026].
What is differentiated, according to the company-linked reporting, is the anatomy-driven closure approach rather than a standard fixed metal occluder [Polsky Center, October 2026]. The stated mechanism combines temporary structural control with gel delivery to address clot formation in the left atrial appendage, which the source describes as a major source of embolic stroke in AFib [Polsky Center, October 2026]. That said, all of the technical detail in public view appears to trace back to company or university-affiliated announcements, so the claims should be read as product intent rather than external validation [Polsky Center, June 2026] [Polsky Center, October 2026].
The development stage is also clear, and it tempers any reading of near-term readiness. The system remains investigational and is being advanced through prototype development, preclinical testing, and later regulatory and clinical milestones, with June 2026 reporting tying early funding to prototype work, preclinical testing, and data generation [Polsky Center, June 2026] [Polsky Center, October 2026]. No verified demo, FDA clearance, human deployment, or named clinical site was confirmed in the materials provided, which keeps the technology case interesting but still largely preclinical from a public diligence standpoint [Polsky Center, June 2026] [Chicago Business Journal, October 2026].
Unconfirmed -- Material product and stage claims in this section rely primarily on company and university-affiliated announcements, with limited third-party corroboration from PitchBook and press coverage.
Market Size and Demand
From the public record This market matters now because left atrial appendage closure sits at the intersection of a large, aging atrial fibrillation population and a procedural cardiology workflow that still leaves room for device design changes, even before Parasol itself has reached the clinic [Polsky Center, October 2026].
The constraint in public research is straightforward: there is no source in the captured record that provides a verified TAM, SAM, or SOM specifically for patient-specific left atrial appendage closure devices or for Parasol's target subsegment. The cleaner approach is to anchor on the addressable clinical problem rather than invent precision. Public materials consistently place Parasol in stroke prevention for people with atrial fibrillation through left atrial appendage closure, with transcatheter delivery and an investigational non-permanent implant approach [Polsky Center, October 2026] [PitchBook]. That frames the relevant market as structural heart intervention, more specifically LAA closure, with adjacent exposure to electrophysiology, interventional cardiology, and stroke-prevention device budgets at hospitals and health systems [Polsky Center, June 2026] [Chicago Business Journal, October 2026].
Demand drivers are visible even in the limited source set. The clinical rationale behind the category is that clot formation in the left atrial appendage is a major source of embolic stroke in atrial fibrillation, which is the core problem Parasol's system is intended to address [Polsky Center, October 2026]. On the procedure side, the company's positioning suggests a persistent unmet need around anatomical variability and permanent metal implants, since its differentiation is an anatomy-driven closure approach that aims to conform to individual patient anatomy and reduce the need for a permanent metal implant [Polsky Center, October 2026]. That does not prove market adoption, but it does identify the tailwind: operators and hospitals may be receptive to alternatives if they can preserve transcatheter workflow while improving fit or reducing implant burden.
Adjacent and substitute markets matter here because Parasol will not be evaluated in isolation. The most direct substitute is continued use of existing LAA closure approaches built around permanent occlusion implants, which is the comparison implied by both the Polsky Center description and trade coverage describing the device as implant-free or non-metallic in intent [Polsky Center, October 2026] [Dealroom News] [Chicago Business Journal, October 2026]. Beyond device substitutes, the broader stroke-prevention pathway for atrial fibrillation includes medical management and other cardiology-led treatment choices, which means Parasol's eventual commercial market will depend not only on device performance but also on where clinicians place LAA closure in the treatment algorithm. Public sources do not quantify those adjacent markets, so the present conclusion is qualitative rather than size-based.
Regulatory and macro forces are also easy to name and harder to handicap from public evidence. The company is still in prototype development and preclinical testing, with future regulatory and clinical milestones ahead, so market timing is inseparable from FDA pathway execution and eventual human data generation [Polsky Center, June 2026] [Polsky Center, October 2026]. At the same time, UCM Ventures and Cardiovascular Innovation Ventures participating in the pre-seed round suggests institutional interest from investors close to academic medicine and cardiovascular practice, which can be helpful in a category where reimbursement, physician training, and evidence generation usually shape adoption more than pure software-style go-to-market speed [Polsky Center, October 2026].
| Market frame | Public evidence | Relevance to Parasol |
|---|---|---|
| Core market | Investigational LAA closure for stroke prevention in atrial fibrillation [Polsky Center, October 2026] | Direct category alignment |
| Adjacent buyer environment | Interventional cardiology and hospital-based procedural care implied by transcatheter delivery and LAA closure workflow [Polsky Center, June 2026] [PitchBook] | Likely clinical and economic buying context |
| Primary substitute | Permanent metal implant-based LAA occlusion approaches, cited implicitly by Parasol's non-permanent positioning [Polsky Center, October 2026] [Chicago Business Journal, October 2026] | Defines the incumbent standard Parasol must displace |
| Commercial gating factors | Preclinical status, future regulatory milestones, and need for testing data [Polsky Center, June 2026] [Polsky Center, October 2026] | Adoption timing depends on evidence and clearance |
The table shows why this market reads as strategically interesting but still immature from an investor evidence standpoint. The clinical problem and incumbent workflow are visible in public sources, while hard market sizing and adoption curves are not yet established in the sourced record.
Single-source, plausible -- Section rests on one independent outlet plus company-affiliated Polsky Center reporting, with no third-party market sizing report in the captured sources.
Who Else Is Fighting for This
Positioning
MIXED Parasol Med Tech is not competing for share in an established commercial device lane yet, it is competing for relevance against existing left atrial appendage closure practice, adjacent stroke-prevention pathways, and better-capitalized structural heart programs that already own physician attention [Polsky Center, October 2026] [PitchBook].
The competitive map starts with incumbents in stroke prevention for atrial fibrillation, even where the retrieved sources do not name individual device makers. In practical terms, Parasol is entering a care pathway where physicians already have alternatives: long-term anticoagulation, conventional left atrial appendage closure procedures using permanent implant-based approaches, and the option to defer new-device adoption until stronger clinical evidence exists [Polsky Center, October 2026]. That matters because an investigational catheter-and-gel system does not only need to prove it works, it needs to displace familiar treatment patterns in an area where procedural trust and evidence depth tend to matter more than novelty alone [Polsky Center, June 2026] [Chicago Business Journal, October 2026].
Among challengers, the closest competition appears to be other early-stage structural heart or LAA closure programs pursuing less permanent or more anatomy-adaptive approaches, although the supplied public record does not name direct startup peers. That absence does not imply a clear field. It means the public evidence here is still thin, and the company is early enough that the sharper contest may be for capital, key clinical advisors, preclinical validation, and eventual trial design support rather than for current revenue or signed hospital accounts [Polsky Center, June 2026] [Polsky Center, October 2026]. In that frame, adjacent substitutes include any intervention that lets electrophysiology or interventional cardiology teams manage AFib-related stroke risk without adopting a new investigational platform [Polsky Center, October 2026].
Parasol's edge today is specific rather than broad. The company is built around founder-domain expertise in LAA closure and catheter-based intervention through Atman Shah's clinical background at the University of Chicago, and it has early institutional support from the George Shultz Innovation Fund, Harper Court Ventures, UCM Ventures, and Cardiovascular Innovation Ventures [Polsky Center, June 2026] [Polsky Center, October 2026]. That combination can help with prototype refinement, access to clinical feedback, and credibility with future medtech investors. Still, the durability of that edge looks perishable until it is converted into harder assets such as defensible IP, preclinical data, regulator-ready evidence packages, and named development or manufacturing partners. Clinical insight is a real starting advantage, but by itself it is not a lasting moat in device categories where larger players can often respond once a design thesis looks validated [Polsky Center, June 2026] [Polsky Center, October 2026].
The exposure is also fairly clear. Incumbent device ecosystems, even unnamed in the retrieved record, likely have a large advantage in physician relationships, trial infrastructure, reimbursement experience, and downstream commercialization resources. Parasol does not yet appear to have publicly verified clinical deployments, regulatory clearance, named hospital customers, or disclosed strategic manufacturing partners, which leaves it vulnerable if competing programs move faster from concept into formal evidence generation [Polsky Center, June 2026] [Polsky Center, October 2026]. It is also exposed to categories it does not yet control, especially hospital procurement and broad distribution, because an anatomy-driven device concept still has to pass through the slowest gates in medtech: reproducible manufacturing, preclinical safety, clinical study design, and adoption by procedure-focused specialists [Polsky Center, October 2026] [Chicago Business Journal, October 2026].
Over the next 18 months, the most plausible competitive scenario is a sorting event based on evidence rather than branding. Parasol is the likely winner if its patient-specific, non-permanent closure thesis produces convincing preclinical results and translates into a credible regulatory path, because that would turn its current academic and investor support into a stronger position with strategic partners and future financers [Polsky Center, June 2026] [Polsky Center, October 2026]. Parasol is also the likely loser if investigational progress stalls at prototype or animal-testing stages while established LAA closure pathways remain clinically adequate for most operators, since the company does not yet appear to own a distribution channel or a public data advantage that can compensate for slower technical validation [Polsky Center, October 2026] [PitchBook].
Unconfirmed -- This section relies primarily on company-linked and university-affiliated announcements, with partial corroboration from PitchBook and business press, but no named direct competitors were confirmed in the supplied public record.
Opportunity
PUBLIC
The prize here is unusually large for a company this early because a credible alternative to permanent metal left atrial appendage closure could matter at the level of procedure standard of care, not just product line extension, if Parasol can carry an investigational concept through preclinical, regulatory, and clinical proof [Polsky Center, October 2026].
The headline opportunity is to become a differentiated structural-heart platform around patient-specific left atrial appendage closure for atrial fibrillation patients, starting with a single procedure category where device fit and anatomy matter acutely [Polsky Center, October 2026]. That is still a conditional outcome, but the path is more than aspirational because the company is not beginning from a generic software claim or an undifferentiated implant concept. Public sources describe a catheter-and-gel closure system designed to conform to individual patient anatomy and reduce the need for a permanent metal implant, and they tie the invention directly to an interventional cardiology founder whose clinical practice includes catheter-based interventions and LAA closure [Polsky Center, June 2026] [Polsky Center, October 2026]. The financing base also matters. The October 2026 pre-seed brought in Harper Court Ventures, UCM Ventures, and Cardiovascular Innovation Ventures, alongside an earlier George Shultz Innovation Fund award, which suggests early institutional support from parties close to the University of Chicago and cardiovascular care rather than a purely promotional syndicate [Polsky Center, June 2026] [Polsky Center, October 2026].
The upside case still depends on evidence not yet visible in public, especially preclinical performance and eventual human data. Even so, the ingredients of a meaningful company are present: a specific clinical problem, a technically differentiated approach, and early backers with domain proximity [PitchBook, 2026] [Polsky Center, October 2026].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Win the implant-alternative niche | Parasol establishes itself as the preferred option for physicians and hospitals seeking an LAA closure approach that reduces reliance on permanent metal implants | Strong preclinical data followed by clinical evidence that anatomy-conforming closure is feasible and safe | The product is already described as an anatomy-driven catheter-and-gel system built to conform to individual patient anatomy, which is a clear product thesis rather than a broad platform claim [Polsky Center, October 2026] |
| Become a strategic structural-heart asset | A larger cardiovascular device company views Parasol as an acquisition candidate to add a differentiated LAA closure modality to an existing interventional portfolio | De-risking through prototype development, preclinical testing, and early regulatory progress | Public sources place the company squarely in prototype and preclinical work today, which is the stage at which strategic optionality begins to form in medtech if technical data are compelling [Polsky Center, June 2026] [Polsky Center, October 2026] |
| Build a patient-specific closure platform | The initial LAA product becomes the first proof point for a broader platform in anatomy-driven transcatheter closure tools | Repeatable demonstration that patient-specific design improves fit or workflow in one indication | PitchBook describes the company as developing patient-specific LAA closure implants with transcatheter delivery capability, which supports the idea that customization is part of the product architecture, not a marketing layer [PitchBook, 2026] |
What compounding looks like in this business is clinical and institutional, not viral. If Parasol can show that patient-specific closure improves procedural fit or expands candidacy in cases where fixed-form devices are harder to use, one successful data set can feed several reinforcing loops: physician interest, stronger hospital adoption discussions, more credible regulatory planning, and better access to later capital [Polsky Center, October 2026]. The public record suggests the flywheel is beginning at the very first turn. The founder is a University of Chicago cardiologist with direct LAA closure experience, the company is described as a University of Chicago spinout, and UCM Ventures participated in the pre-seed round, which can help with translational access and institutional credibility even before commercial traction exists [Polsky Center, June 2026] [Polsky Center, October 2026].
There is also a financing compounding effect if technical milestones are met. The company moved from a $250,000 university-linked innovation investment in June 2026 to a $2.75 million oversubscribed pre-seed by October 2026, a meaningful step-up in a four-month window that indicates the story has already broadened beyond one internal funding source [Polsky Center, June 2026] [Polsky Center, October 2026]. That does not validate the device, but it does show early capacity to convert technical narrative into follow-on institutional support.
The size of the win is best framed through strategic relevance rather than a precise valuation claim, because no public market comparable or category TAM is provided in the source set. If the "strategic structural-heart asset" scenario plays out, the company could become valuable enough to attract acquisition interest from established cardiovascular device platforms looking for differentiated LAA closure technology, especially if it reaches human-proof milestones with a clear non-metallic or anatomy-conforming advantage over conventional approaches [Chicago Business Journal, October 2026] [Polsky Center, October 2026]. Any dollar figure beyond that would be speculative on the current evidence. The more defensible point is that this is one of the narrower but potentially very consequential medtech bets, where success in a single procedure domain can create platform-level strategic value far above current capitalization (scenario, not a forecast) [Polsky Center, October 2026].
Unconfirmed -- This section relies materially on company-linked and university-linked reporting for product claims and milestone status, with limited independent corroboration from PitchBook and Chicago Business Journal.
Sources
From the public record
[Polsky Center, October 2026] Founded by UChicago Cardiologist, Parasol Secures $2.75M for Novel Medical Device to Improve Stroke Prevention | https://polsky.uchicago.edu/2026/10/26/founded-by-uchicago-cardiologist-parasol-secures-2-75m-for-novel-medical-device-to-improve-stroke-prevention/
[Polsky Center, June 2026] George Shultz Innovation Fund Awards $250K to Parasol Medtech and Signl | https://polsky.uchicago.edu/2026/06/17/george-shultz-innovation-fund-awards-250k-to-parasol-medtech-and-signl/
[LinkedIn, 2026] Evan Singer - San Francisco, California, United States | Professional Profile | LinkedIn | https://www.linkedin.com/in/evan1singer/
[Global Deal Flow, 2026] Parasol Med Tech, Inc. raised $2.4M | Global Deal Flow | https://globaldealflow.com/deals/parasol-med-tech-inc
[Chicago Business Journal, October 2026] UChicago spinout raises $2.75M for medical device to prevent strokes | https://www.bizjournals.com/chicago/news/2026/10/28/parasol-med-tech-afib-heart-device.html
Articles about Parasol Med Tech
- A $3 Million Pre-Seed Funds a Gel Alternative to Heart Implants — The University of Chicago spinout, backed by the ACC's venture arm, is developing an anatomy-driven LAA closure system that could reduce reliance on permanent metal implants.